1.      Ascott A, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis. J Allergy Clin Immunol. 2019;143:1821–1829.

2.      Asher MI, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three. Lancet. 2006;368:733–743.

3.      Beck LA, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.

4.      Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter-update 2015. J Allergy Clin Immunol Pract. 2015;3(3 Suppl):S1–S39.

5.      Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with tralokinumab monotherapy (ECZTRA 1 and ECZTRA 2): results of two 52-week, randomized, double-blind, placebo-controlled, phase 3 trials. Br J Dermatol. 2021;184(3):437–449.

6.      Chandler DJ, Fuller LC. A review of scabies: an infestation more than skin deep. Dermatology. 2019;235(2):79–90.

7.      Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137:26–30.

8.      Eichenfield LF, Ahluwalia J, Waldman A, et al. Atopic dermatitis: current insights into pathophysiology and emerging therapies. Ann Allergy Asthma Immunol. 2023;131(6):739–749.

9.      Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70:338–351.

10.  Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.

11.  Elias PM, et al. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121:1337–1343.

12.  Guttman-Yassky E, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124:1235–1244.

13.  Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol Suppl. 1980;92:44–47.

14.  Irvine AD, et al. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327.

15.  Johansson SG, et al. Revised nomenclature for allergy for global use: report of the WAO. J Allergy Clin Immunol. 2004;113:832–836.

16.  Kong HH, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850–859.

17.  Leshem YA, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement. J Am Acad Dermatol. 2020;82:1181–1186.

18.  Palmer CN, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446.

19.  Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib in patients with moderate-to-severe atopic dermatitis: results from two randomized, double-blind, placebo-controlled phase 3 trials. Br J Dermatol. 2020;183(2):242–252.

20.  Ruzicka T, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376:826–835.

21.  Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.

22.  Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873.

23.  Sonkoly E, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–417.

24.  Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118–S127.

25.  Spuls PI, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials. Br J Dermatol. 2017;176:979–984.

26.  Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. JAMA Dermatol. 2015;151(5):513–521.

27.  Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children. J Am Acad Dermatol. 2010;62(6):979–987.

28.  Weidinger S, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.

29.  Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.

30.  Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352:2314–2324.

31.  Wollenberg A, et al. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol. 2003;112:667–674.